Global Hemiplegic Migraine Market to worth USD 1.69 Billion at a CAGR of 2.90% By 2030

The Hemiplegic Migraine Market is expected to reach USD 1.69 Billion by 2030 at 2.90% CAGR during the forecast period 2022-2030

The Hemiplegic Migraine Market is growing pervasively mainly due to the growing rate of hemiplegic migraine and the availability of its treatments. Over the past few years, the prevalence of hemiplegic migraine has been increasing rapidly. Familial hemiplegic migraine (FHM) is a hereditary condition which means children of parents affected with FHM have 50% of chances having FHM.

The other type, sporadic hemiplegic migraine (SHM) is more of a lifestyle-based disorder related to addictions to alcohol and caffeine, habit of skipping meals, weather changes, growing pollutions, etc. Resultantly sporadic hemiplegic migraine is more prevalent than FHM.

However, there are a number of treatment methods available to treat both the types of hemiplegic migraines owing to the technological advancements that happened in the field of medical science in the recent years. Growing prevalence and the availability of treatments are the two key driving forces behind the market growth of hemiplegic migraines.

The hemiplegic migraine treatment is a well-established market having a number of treatment methods and medicines available to cure the condition. Increasing technological advancements in the field of medical science drive the market growth. The global hemiplegic migraine market is heading with the pervasively rising number of patients suffering from hemiplegic migraine led by the changing lifestyle.

On the flip side, factors such as the side-effects associated with migraine treatment drugs are obstructing the market growth.

Hemiplegic Migraine Market – Segmentations

The global hemiplegic migraine market has been segmented on the basis of type, treatment, preventive treatment, distribution channel, end-user, and region. By type, the market is segmented into familial hemiplegic migraine and sporadic hemiplegic migraine. By end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

By treatment, the market is segmented into acute treatment, triptans, ergotamines, nsaids, antiemetics, narcotic analgesics, and others. By preventive treatment, the market is segmented into antidepressants, botox injections, and others. By distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others. By region, the market is segmented into the Americas, Europe, Asia-Pacific, and Middle East & Africa.

Hemiplegic Migraine Market - Geographical Analysis

North America accounts for the leading market for the hemiplegic migraine. Factors positively impacting the market growth in the region include the high per capita health care expenditures and rapid uptake of advanced technologies in the growing healthcare sector. Moreover, the increasing prevalence of hemiplegic migraine are fuelling the market growth in the region. Furthermore, the presence of well-established market players is positively impacting the growth in the regional market.

The Europe hemiplegic migraine market accounts for the second-largest market, globally.  Attributing to the increasing healthcare expenditure, availability of advanced treatment facilities, and government initiatives, the market is estimated to register a remarkable CAGR during the forecast period (2018-2023).

The hemiplegic migraine market in the Asia Pacific region is rapidly emerging as a promising market. Growing population alongside the growing prevalence of hemiplegic migraine is driving the market in the region. Also, some of the other dominant factors such as the faster adoption of healthcare technology and government initiatives to improve the quality of healthcare are fostering the growth of the APAC market.

Hemiplegic Migraine Market - Key Players

Some of the market leaders profiled in the report are Abbott Laboratories, Allergan Plc., AstraZeneca, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Impax Laboratories, Eli Lily and Company, Johnson & Johnson, and Merck & Co.

Innovation, mergers & acquisitions, product launch, and regional expansion remain the key trends for these players to maintain their market positions.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Hemiplegic Migraine Market Research Report